The Afraxis technology platform and PAK program provide a number of opportunities for potential partners; please contact us directly to discuss these alternatives.
PAK programAfraxis seeks a partner for its PAK inhibitor program for the treatment of CNS disorders in order to rapidly advance this program to clinical trials.
Research and DevelopmentPartners can evaluate their compounds in our high content platform to determine a compound's effect on dendritic spine shape and synapse function. Combined with animal efficacy studies, this enables a partner to prioritize compounds for clinical development with an increased likelihood of exhibiting efficacy in human trials.
ReprofilingA partner can evaluate development or clinical stage compounds whose advancement have been discontinued in our high content platform to reposition the compounds into alternative CNS indications.
In-licensingAfraxis seeks to identify compounds with demonstrated safety and pharmacokinetic profiles that improve dendritic spine and synapse function for its own development portfolio.
